scholarly journals A Severe Case of Lymphomatoid Papulosis Type E Successfully Treated with Interferon-Alfa 2a

2017 ◽  
Vol 2017 ◽  
pp. 1-5 ◽  
Author(s):  
Aslı Bilgiç Temel ◽  
Betül Unal ◽  
Hatice Erdi Şanlı ◽  
Şeniz Duygulu ◽  
Soner Uzun
Keyword(s):  
Spontaneous Regression ◽  
Cell Lymphoma ◽  
Severe Case ◽  
Interferon Alfa ◽  
Treatment Modalities ◽  
Lymphomatoid Papulosis ◽  
Histological Features ◽  
Remission Status ◽  
First Case ◽  
New Variant

Lymphomatoid papulosis (LyP) is a benign papulonodular skin eruption with histologic features of malignant lymphoma. A new variant of LyP which was termed “type E” was recently described with similar clinical and histological features to angiocentric and angiodestructive T-cell lymphoma. LyP type E is characterized with recurrent papulonodular lesions which rapidly turn into hemorrhagic necrotic ulcers and spontaneous regression by leaving a scar. None of the available treatment modalities affects the natural course of LyP. For therapy various modalities have been used such as topical and systemic steroids, PUVA, methotrexate, bexarotene, and IFN alfa-2b. Here we present a severe and devastating case with a very rare variant of LyP type E, which is, to our knowledge, the first case successfully treated with IFN alfa-2a. Now disease has been maintaining its remission status for six months.

Lymphomatoid papulosis presenting as a rash in a patient with HIV infection

2018 ◽  
Vol 29 (11) ◽  
pp. 1120-1122
Author(s):  
Sian Warren ◽  
Vincent Li ◽  
Rachel Drayton ◽  
Kenneth May
Keyword(s):  
Differential Diagnosis ◽  
Hiv Infection ◽  
Spontaneous Regression ◽  
Clinical Course ◽  
Cell Lymphoma ◽  
Correct Diagnosis ◽  
Daily Basis ◽  
Combination Antiretroviral Therapy ◽  
Lymphomatoid Papulosis ◽  
History Of

A 43-year-old Malaysian man with well-controlled HIV infection on combination antiretroviral therapy presented with a six-week history of a widespread rash. The patient was otherwise well but was developing new lesions on a daily basis. Referral to Dermatology instigated punch biopsies, which revealed a diagnosis of lymphomatoid papulosis type A. This case highlights the importance of swift referral, especially in cases of spontaneous regression of symptoms, in order to obtain the correct diagnosis. In most patients, this condition tends to be chronic, with its chronicity and benign clinical course setting it apart from cutaneous anaplastic T-cell lymphoma and Hodgkin’s disease, which are major entities in the histological differential diagnosis.

Treatment Modalities and Survival Outcomes for Sinonasal Diffuse Large B‐Cell Lymphoma

2021 ◽  
Author(s):  
Brandon M. Lehrich ◽  
Arash Abiri ◽  
Khodayar Goshtasbi ◽  
Jack Birkenbeuel ◽  
Tyler M. Yasaka ◽  
...  
Keyword(s):  
B Cell ◽  
Cell Lymphoma ◽  
B Cell Lymphoma ◽  
Treatment Modalities ◽  
Survival Outcomes ◽  
Large B Cell Lymphoma ◽  
Large B Cell

scholarly journals Clinical, Laboratory and Histological Features of Dipeptidyl Peptidase-4 Inhibitor Related Noninflammatory Bullous Pemphigoid

2021 ◽  
Vol 10 (9) ◽  
pp. 1916
Author(s):  
Ágnes Kinyó ◽  
Anita Hanyecz ◽  
Zsuzsanna Lengyel ◽  
Dalma Várszegi ◽  
Péter Oláh ◽  
...  
Keyword(s):  
Bullous Pemphigoid ◽  
Clinical Laboratory ◽  
Case Series ◽  
Dipeptidyl Peptidase ◽  
Area Index ◽  
Histological Features ◽  
Dipeptidyl Peptidase 4 ◽  
First Case ◽  
Dipeptidyl Peptidase 4 Inhibitor ◽  
The Mean

Bullous pemphigoid (BP) is an autoimmune blistering disease of elderly patients that has shown increasing incidence in the last decades. Higher prevalence of BP may be due to more frequent use of provoking agents, such as antidiabetic dipeptidyl peptidase-4 inhibitor (DPP4i) drugs. Our aim was to assess DPP4i-induced bullous pemphigoid among our BP patients and characterize the clinical, laboratory and histological features of this drug-induced disease form. In our patient cohort, out of 127 BP patients (79 females (62.2%), 48 males (37.7%)), 14 (9 females and 5 males) were treated with DPP4i at the time of BP diagnosis. The Bullous Pemphigoid Disease Area Index (BPDAI) urticaria/erythema score was significantly lower, and the BPDAI damage score was significantly higher in DPP4i-BP patients compared to the nonDPP4i group. Both the mean absolute eosinophil number and the mean periblister eosinophil number was significantly lower in DPP4i-BP patients than in nonDPP4i cases (317.7 ± 0.204 vs. 894.0 ± 1.171 cells/μL, p < 0.0001; 6.75 ± 1.72 vs. 19.09 ± 3.1, p = 0.0012, respectively). Our results provide further evidence that DPP4i-associated BP differs significantly from classical BP, and presents with less distributed skin symptoms, mild erythema, normal or slightly elevated peripheral eosinophil count, and lower titers of BP180 autoantibodies. To our knowledge, this is the first case series of DPP4i-related BP with a non-inflammatory phenotype in European patients.

scholarly journals Infective Aortic Valve Endocarditis Causing Embolic Consecutive ST-Elevation Myocardial Infarctions

2019 ◽  
Vol 2019 ◽  
pp. 1-5
Author(s):  
Kanksha Peddi ◽  
Alexander L. Hsu ◽  
Tomas H. Ayala
Keyword(s):  
Myocardial Infarction ◽  
Infective Endocarditis ◽  
Aortic Valve ◽  
Index Case ◽  
Current Treatment ◽  
Myocardial Infarctions ◽  
Treatment Modalities ◽  
The Past ◽  
First Case ◽  
St Elevation

ST-elevation myocardial infarction (STEMI) is a rare and potentially fatal complication of infective endocarditis. We report the ninth case of embolic native aortic valve infective endocarditis causing STEMI and the first case to describe consecutive embolisms leading to infarctions of separate coronary territories. Through examination of this case in the context of the previous eight similar documented cases in the past, we find that infective endocarditis of the aortic valve can and frequently affect more than a single myocardial territory and can occur consecutively. Further, current treatment modalities for embolic infective endocarditis causing acute myocardial infarction are limited and unproven. This index case illustrates the potential severity of complications and the challenges in developing standardized management for such patients.

Hodgkin's Disease, Lymphomatoid Papulosis, and Cutaneous T-Cell Lymphoma Derived from a Common T-Cell Clone

1992 ◽  
Vol 326 (17) ◽  
pp. 1115-1122 ◽  
Author(s):  
Thomas H. Davis ◽  
Cynthia C. Morton ◽  
Robert Miller-Cassman ◽  
Steven P. Balk ◽  
Marshall E. Kadin
Keyword(s):  
T Cell ◽  
Hodgkin's Disease ◽  
Cell Lymphoma ◽  
Cell Clone ◽  
Hodgkin’S Disease ◽  
T Cell Lymphoma ◽  
Cutaneous T Cell Lymphoma ◽  
Lymphomatoid Papulosis ◽  
T Cell Clone
Sign in / Sign up

Export Citation Format

Share Document